How the Dow's Pharma Stocks Have Fared in 2013

Before you go, we thought you'd like these...
Before you go close icon

The Dow Jones Industrial Average isn't just for industrial stocks anymore. You can find all sorts of companies in the venerable average, with the Dow representing a nearly all-inclusive cross-section of the entire U.S. economy.

Pharma stocks aren't a huge part of the Dow, with just two of its constituents focused solely on the space and a third reaping a substantial portion of its revenue from pharmaceuticals. Yet pharma stocks have made a big impression on investors because of their lucrative dividend yields. Let's take a look at how these companies have fared so far in 2013 and what their prospects are for the rest of the year and beyond.

JNJ Total Return Price Chart


JNJ Total Return Price data by YCharts.

You may not think of Johnson & Johnson as a pharmaceutical company, as it's far better-known for its consumer products. But the health care conglomerate also produces proprietary drugs and medical devices, giving it a broad reach over the entire health care industry. Lately, even as the company has faced liability from recalls of its artificial hip replacements, Johnson & Johnson has gotten help from its pharma division, as the approval of its type 2 diabetes drug Invokana represents a big step forward in diabetes treatment that could produce the company's next blockbuster.

Meanwhile, pure pharma stocks Pfizer and Merck have both dealt with patent expirations of high-profile drugs over the past couple of years, including Merck's Singulair and Pfizer's Lipitor. Yet while revenue has predictably fallen since generic competition hit the market, both companies have held up better than pessimists had expected.

For Pfizer, anticlotting drug Eliquis, which it co-developed with Bristol-Myers Squibb, has the potential to generate billions in sales over the next decade, having several advantages over rival drugs designed to replace the existing warfarin treatment for atrial fibrillation. Merck still faces some patent-cliff problems, with Vytorin, Nasonex, and Zetia coming off patent over the next four years. But with the combination of existing diabetes drugs Januvia and Janumet and up-and-coming development-stage drugs like insomnia treatment suvorexant and osteoporosis drug odanacatib, Merck has good prospects looking forward.

Keep looking for healthy results
With the pharma industry having turned the patent-cliff corner, pharma stocks should continue contributing to the Dow's overall success. Given the emphasis on dividend income, the big yields that Pfizer and Merck pay will likely remain big drawing points for years to come.

As big as Johnson & Johnson is in health care, some critics are convinced that the company is spread too thin. Is Johnson & Johnson overextended, or is it a well-diversified health-care giant that deserves a place in your portfolio? Find out our view by checking out the Fool's new premium report. Inside, our analyst outlines the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now

The article How the Dow's Pharma Stocks Have Fared in 2013 originally appeared on Fool.com.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners